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Abstract 
The ABO blood group locus was recently found to contribute independently as well as via interactions 
with ACE gene variation to plasma levels of angiotensin converting enzyme (ACE). Variation in ACE 
has also previously been implicated as conferring susceptibility for Alzheimer’s disease (AD), but has 
also been proposed to confer risk via interactions with other as yet unknown genes. More recently, 
larger studies have not supported ACE as a risk factor for AD, while the role of ACE pathway in AD 
has come under increased levels of scrutiny with respect to various aspects of AD pathology and 
possible therapies. We explored the potential combined involvement of ABO and ACE variation in the 
genetic susceptibility of 2067 AD cases compared to 1376 non-demented elderly. Including the effects 
of ABO haplotype did not provide any evidence for the genetic association of ACE with AD.  
1. Introduction 
The renin angiotensin system (RAS) has become a biological pathway of increasing interest in the 
pathogenesis of Alzheimer’s disease (AD) and potentially as a basis for future interventions. Previous 
genetic associations between ACE, that encodes for angiotensin converting enzyme (ACE), one of 
the key enzymes in the RAS, played a significant role in the growing interest of this system in AD. 
This was aided by the fact that the suggested ACE risk variant contributed to lower levels of plasma 
ACE while it was also shown that ACE degraded amyloid-β peptide, which is widely involved in the 
pathology of AD (reviewed in Kehoe and Wilcock, 2007). However, more recent haplotype studies 
and Genome Wide Association Studies (GWAS) have not supported the role of ACE as a genetic risk 
factor for AD. Previous meta-analyses have suggested however the possibility that ACE may mediate 
risk via epistatic interactions with other genetic risk variants (Lehmann et al., 2005).  
Recently it was shown that the variants in the ABO blood group locus, independently and when 
combined with ACE variants, explained a greater proportion of the population variance of ACE in 
plasma than ACE alone (Terao et al., 2013).  In particular, alleles tagging the ABO blood group Type 
A1 were associated with the lowest plasma ACE activity, while alleles tagging Type B were 
associated with increased ACE activity and Type A2 and O alleles were associated with intermediate 
activity (Terao et al., 2013). Given the previously suggested role of ACE activity in AD (Miners et al., 
2008) we investigated whether variation in ABO when combined with ACE variation might be 
associated with increased risk of AD. 
2. Methods 
A combined GWAS dataset of 3448 samples from Alzheimer’s Research UK (ARUK) and the Mayo 
Clinic genotyped on Illumina HumanHap300v1 was used. All samples were of European descent, 
1487 males and 1922 females, 2069 cases with average age at death of 73.5 years (range 51-108) 
and 1379 controls with average age at death of 73.4 years (range 54-97 years), with APOE alleles: ε2 
- 5.7%; ε3 - 65.9%; ε4 - 28.4%. The power of the study to detect an association with AD was 
calculated in QUANTO v1.2.4. 
The ABO and ACE regions were imputed against 1000 Genomes Phase I haplotypes in IMPUTE2. 
Imputed data was further quality control checked resulting in 4599 SNPs in ACE for association 
testing. ABO blood group haplotypes were determined from the imputed ABO region and included as 
a covariate for the merged dataset. The imputed ACE region was association tested in PLINK (Purcell 
et al., 2007) using logistic regression corrected for sex, age at onset and APOE ε4 allele and including 
ABO type as an interaction term. The association test was also run including the blood group B allele 
and A1 allele separately as interaction terms. The power of the study to detect the interaction was 
calculated post-hoc using G*Power. For further details please see the supplementary materials. 
3. Results 
Power calculations in QUANTO v1.2.4 indicated 71% to 99% power at this sample size to detect an 
association with a genetic variant with MAF of 1% to 5% assuming a genetic odds ratio of 1.2 to 1.5.  
ABO blood group haplotype was determined for 3396 samples, as the genotype was not available for 
all samples. The logistic regression model corrected for sex, age at onset and APOE ε4 allele dose 
and provided no evidence to support an ACE association with disease in this dataset (Suppl. Table 2, 
Suppl. Fig 1-3).  
Additionally, the interaction terms of ABO blood type and ACE variant and the interaction terms for the 
presence of a B allele or A1 allele and ACE variants were not significantly associated with disease 
status and failed to improve the model containing only covariates (Suppl. Table 2, Suppl. Fig 4,5). 
Post-hoc power analysis showed that the effective power was 77% to 83%. 
4. Discussion 
In this report we have determined if ABO blood type can potentially modify any association of ACE 
gene variation with AD.  To address this issue we have used ABO haplotypes (both A1 and B alleles), 
modelling interactions reported for ABO with ACE on plasma ACE levels, to explore whether it had 
any additional effects on ACE SNP associations with AD (Suppl. Fig 1-5). It should be noted that the 
majority of these cases were pathologically confirmed as AD so the contribution to vascular AD, which 
is biologically plausible, remains to be determined. 
In summary, we find no evidence to support a role for ACE, modelled with ABO locus genotypes, 
being associated with the risk of developing AD. 
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